MBIO
Mustang Bio, Inc.1.0700
-0.0600-5.31%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
7.81MP/E (TTM)
-Basic EPS (TTM)
-6.71Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
Mustang Bio narrowed its Q2 net loss to $0.8M from $8.2M a year earlier, thanks to slashed R&D spending after workforce cuts and lease terminations, while interest income climbed to $0.1M. Operating expenses dropped 90% year-over-year to $0.9M, reflecting a leaner operation focused on CAR T therapies for cancers and autoimmune diseases. Cash swelled to $12.7M by quarter-end, bolstered by $6.8M from a February equity offering and $0.6M via at-the-market sales, though free cash flow isn't disclosed in the 10-Q. The company sold off equipment in February for $1.2M, streamlining assets. Yet regulatory hurdles loom large in advancing clinical trials.
8-K
FDA Orphan Designation for MB-101
Mustang Bio secured FDA Orphan Drug Designation for MB-101, its IL13Ra2-targeted CAR T-cell therapy, to treat recurrent astrocytomas and glioblastoma on July 7, 2025. This grants tax credits, fee waivers, and seven years of market exclusivity for these rare cancers affecting under 200,000 U.S. patients. Phase 1 data showed 50% of patients achieving stable disease or better, including two complete responses lasting 7.5 and 66+ months. Yet advancing the MB-101 and MB-108 combination hinges on fresh funding.
10-Q
Q1 FY2025 results
Mustang Bio narrowed its Q1 FY2025 net loss to $0.2M from $5.2M a year earlier, thanks to sharp cuts in R&D spending after workforce reductions and lease terminations, while G&A dipped 15% y/y. Operating expenses fell 95% y/y to $0.3M, with a $0.4M gain from ending the Plantation Street lease boosting the bottom line; interest income rose 150% y/y to $0.1M. Cash swelled to $14.2M on $7.6M from equity raises, including a February offering, but free cash flow isn't disclosed in the 10-Q. The firm sold equipment for $1.2M and shifted to Fortress's Waltham space. No revenue yet, as CAR T trials pivot to partners like Fred Hutch. Substantial doubt lingers on going-concern viability without fresh funding.
10-K
FY2024 results
Mustang Bio's FY2024 results showed a narrowed net loss of $15.8 million, down 69% from $51.6 million in 2023, driven by an 81% cut in R&D spending to $7.6 million after workforce reductions and program terminations, including the MB-106 hematologic trial. Q4 momentum centered on FDA Orphan Drug Designation for MB-108 in malignant glioma and planning for investigator-sponsored Phase 1 trials of MB-109 (brain tumors) and MB-106 (autoimmune diseases) at partner sites in Q4 2025, while FY expenses dropped 67% overall. Cash stood at $6.8 million, bolstered by $11.2 million in equity raises, but liquidity remains tight with no revenue and ongoing losses. Year-end debt was zero after 2023 repayment, with capex minimal post-facility sale; no dividends or buybacks occurred. No annual guidance was provided, but focus shifts to third-party funding for pivotal trials. Substantial doubt persists on going concern amid funding needs.
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
CRBU
Caribou Biosciences, Inc.
1.69-0.02
ESLA
Estrella Immunopharma, Inc.
1.63-0.18
INAB
IN8bio, Inc.
1.50-0.10
LIANY
LianBio
0.09+0.00
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MRKR
Marker Therapeutics, Inc.
1.27-0.12
TNGX
Tango Therapeutics, Inc.
8.96-0.16
XLO
Xilio Therapeutics, Inc.
0.65+0.00